MentalHealthDaily

Anti-CGRP Monoclonal Antibodies to Prevent Chronic Migraine (2023 Review)

Migraine, a primary headache disorder, significantly impacts the quality of life of millions worldwide. In recent years, the focus has shifted toward developing targeted therapies, particularly monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP), to prevent chronic migraine attacks. A relatively recent comprehensive network meta-analysis (NMA) evaluated the efficacy and safety of various anti-CGRP mAbs, …

Topamax (Topiramate) For Migraines: An Effective Prophylactic?

by GLOOM

Topamax (Topiramate) is an anticonvulsant agent discovered in 1979 by Bruce Maryanoff and Joseph Gardocki while working for McNeil Pharmaceutical (a subsidiary of Johnson & Johnson). When compared to other anticonvulsant agents, Topamax is regarded as unique in that it is pharmacologically classified as a sulfamate-substituted monosaccharide derivative, indicating that its chemical structure is similar …

Amitriptyline For Migraines: An Effective Prophylactic Agent

by GLOOM

Amitriptyline (brand name “Elavil”) is a medication that was initially approved by the FDA in 1961 for the treatment of major depressive disorder. Due to its three-ring chemical structure, it is formally classified as a tricyclic antidepressant (TCA). Though not formally approved in the United States to treat conditions other than major depression, Amitriptyline is …